The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.

doi:10.1007/s00228-024-03635-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.

European journal of clinical pharmacology - 1 May 2024

Habibi Mohammad Amin, Mirjani Mohammad Sina, Ahmadvand Muhammad Hussain, Delbari Pouria, Alasti Omid

Abstract excerpt

BACKGROUND: Dabrafenib and trametinib represent targeted therapy options under investigation for treatment of gliomas harboring BRAF V600 mutations. We systematically reviewed the literature and conducted meta-analyses to assess the efficacy and safety of these agents. METHODS: PubMed, Embase, and Scopus were searched from inception to September 2023 for studies examining dabrafenib and/or trametinib for gliomas....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Glioma
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Source

Open in PubMed

Identifiers

PMID: 38345637
DOI: 10.1007/s00228-024-03635-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.